Glucagon-like peptide-1 receptor agonists: Exploring the mechanisms from glycemic control to treatment of multisystemic diseases

Oct 1, 2024World journal of gastroenterology

How glucagon-like peptide-1 receptor agonists work from blood sugar control to treating multiple body diseases

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

GLP-1 receptor agonists (GLP-1RAs) may offer therapeutic potential for metabolic dysfunction-associated fatty liver disease.

GLP-1RAs are already transforming the management of type 2 diabetes mellitus.
They may provide cardiovascular and renal protective effects, particularly in diabetic kidney disease alongside certain medications.
There is evidence suggesting potential benefits for bone health in diabetic osteoporosis.
GLP-1RAs could have neuroprotective properties that may aid in the treatment of Alzheimer's disease by affecting insulin signaling in neurons.
Improvements in hormonal and metabolic profiles in polycystic ovary syndrome have been associated with the use of GLP-1RAs.
Ongoing research is necessary to fully understand the broad therapeutic effects of GLP-1RAs across various systemic diseases.

AI simplified

This editorial takes a deeper look at the insights provided by Soresi and Giannitrapani, which examined the therapeutic potential of glucagon-like peptide-1 receptor agonists (GLP-1RAs) for metabolic dysfunction-associated fatty liver disease. We provide supplementary insights to their research, highlighting the broader systemic implications of GLP-1RAs, synthesizing the current understanding of their mechanisms and the trajectory of research in this field. GLP-1RAs are revolutionizing the treatment of type 2 diabetes mellitus and beyond. Beyond glycemic control, GLP-1RAs demonstrate cardiovascular and renal protective effects, offering potential in managing diabetic kidney disease al-ongside renin-angiotensin-aldosterone system inhibitors. Their role in bone metabolism hints at benefits for diabetic osteoporosis, while the neuroprotective properties of GLP-1RAs show promise in Alzheimer's disease treatment by modulating neuronal insulin signaling. Additionally, they improve hormonal and metabolic profiles in polycystic ovary syndrome. This editorial highlights the multifaceted mechanisms of GLP-1RAs, emphasizing the need for ongoing research to fully realize their therapeutic potential across a range of multisystemic diseases.

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

View full text (HTML) ↗View full text ↗

Glucagon-like peptide-1 receptor agonists: Exploring the mechanisms from glycemic control to treatment of multisystemic diseases

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief